For the first time, Medicare will have the ability to negotiate lower prescription drug prices because of the Inflation Reduction Act, a law that lowers healthcare and prescription drug costs.
The U.S. Department of Health and Human Services has announced a new Office of Family Violence Prevention and Services under the Administration for Children and Families Act.
Two funding opportunities for Certified Community Behavioral Health Clinic expansion, totaling $123.6 million, were made available by the U.S. Department of Health and Human Services.
The U.S. Department of Health and Human Services (HHS) has issued an amendment to the declaration under the Public Readiness and Emergency Preparedness (PREP) Act for medical countermeasures against COVID-19.
A new study shows that a personalized messenger RNA (mRNA) cancer vaccine plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk of recurrence or death in people with high-risk advanced melanoma.
The U.S. Food and Drug Administration has amended the emergency use authorizations of the. Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
A large clinical trial of Eli Lilly's experimental Alzheimer's medication, donanemab found the drug slowed declines in patients' ability to think clearly and perform daily tasks by more than a third.
The U.S. Food and Drug Administration has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata.
The subcutaneous formulation of argenx’s Vyvgart has been approved by the U.S. Food and Drug Administration to treat generalized myasthenia gravis.
The U.S. Food and Drug Administration has approved Roche’s Columvi, an antibody-based therapy chemically known as glofitamab.
Adding an experimental mRNA-based vaccine developed by Moderna and Merck & Co to Keytruda reduced the risk that melanoma would spread by 65 percent over treatment with the immunotherapy drug alone, according to a midstage trial.
The US Food and Drug Administration has granted fast track designation for Kyverna Therapeutics’ KYV-101 to treat refractory lupus nephritis.